MedTrace Logo

A Study of the Pharmacology of Tamiflu in Pregnancy

NCT01203527 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2013-10-09

No results posted yet for this study

Summary

The purpose of this study is to determine the pharmacokinetics (PK) of the anti-flu medication, Tamiflu during pregnancy and to determine to what extent pregnancy may affect the currently recommended dosage of this medication.

Conditions

  • H1N1 Influenza Treatment During Pregnancy

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    lead NIH

Principal Investigators

  • Richard Beigi, MD · University of Pittsburgh

  • Steve Caritis, MD · University of Pittsburgh

  • Raman Venkataramanan, PhD · University of Pittsburgh

Eligibility

Min Age
14 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01203527 on ClinicalTrials.gov